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Problem statement
There is increased recognition that economic evaluation
has limitations because it does not capture a number of
important dimensions of value. This may lead to a lack
of comprehensiveness and a lack of transparency.
Objectives
Past research has indicated that Multiple Criteria
Decision Analysis (MCDA) could be used as an alterna-
tive methodology for assessing the value of new medical
technologies in the context of Health Technology
Assessment (HTA). The objective of this study is to
apply in practice an MCDA framework for the value
assessment of a set of therapeutic options in metastatic
colorectal cancer through a simulation exercise based
on MCDA principles.
Policies targeted
A process to inform the value assessment of new medical
technologies which, in turn, can help determine coverage
decisions and possibly pricing mechanisms.
Stakeholders
All stages of the framework were informed by extensive
stakeholder engagement through their participation at
a decision conference workshop. Stakeholders (13 in
total) included health care professionals (e.g. clinical
experts), methodology experts (e.g. health economists)
and patient advocates (e.g. patients and carers), while
adopting the perspective of a decision-making HTA
body.
Region covered
The context of the study relates to England and Wales at
a national level (EURO region), but it can be applicable
across all WHO regions and levels.
Methods
Study design: experimental case study
Time period: January 2015-May 2015.
Setting: to inform coverage decisions for cancer medi-
cines used in inpatient settings
Interventions: application of a pre-existing methodolo-
gical framework and experimental case study through a
decision conference.
Results
Value parameters considered included therapeutic, safety,
innovation and socioeconomic criteria. Three alternative
treatments were ranked based on their overall value, using
value scores reflecting their performance across all the cri-
teria while considering their relative importance, as
informed through stakeholders’ preferences. Simulation of
payer’s resource allocation decisions on the coverage of
the options were made on value for money grounds
through the use of a “cost-per-unit of value” metric.
Conclusions
MCDA possesses the prerequisites of a value-based assess-
ment methodological framework. The multiplicity of cri-
teria that can be incorporated to assess value, the weights
that can be applied to the criteria and the stakeholders’
involvement across every stage, all of which are fully trans-
parent, provide a unique combination of broadness, resili-
ence and inclusiveness making it an ideal decision-making
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